Otonomy (OTIC) Stock Price
Otonomy Price
Revenue at Otonomy has contracted by 28.7% per year over the past 5 years to 125,000.00 USD. For Otonomy, the net margin of -40,944.8% is down versus -7,268.5% a few years ago.
Otonomy stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Otonomy business model & stock analysis
Frequently asked questions about Otonomy
The main competitors of Otonomy Inc in the market include various pharmaceutical and biotechnology companies involved in the development of innovative therapies for ear-related conditions. Some prominent competitors of Otonomy Inc include Novartis AG, Pfizer Inc, and Johnson & Johnson. These companies also strive to enhance treatment options and improve patient outcomes in the field of otology and related disorders.
The business model of Otonomy Inc focuses on developing and commercializing innovative treatments for diseases and disorders of the ear. The company utilizes its proprietary technology platform to design and deliver drug therapies directly into the ear, targeting specific areas to address conditions such as hearing loss, tinnitus, and ear infections. By focusing on the otology market, Otonomy aims to provide patients with improved treatment options that are more effective and convenient. With a strong emphasis on research and development, Otonomy Inc strives to bring breakthrough therapies to market and make a positive impact on the lives of individuals with ear-related conditions.
Otonomy Inc is primarily active in the biotechnology and pharmaceutical industries.
Otonomy Inc is a biopharmaceutical company specializing in developing and commercializing innovative therapeutics for diseases affecting the ear. Founded in 2008, the company has focused on treating conditions such as Ménière's disease, chronic otitis media, and hearing loss. Otonomy utilizes its proprietary technology, called OTO-313, to deliver targeted drug treatments to the ear, aiming to restore normal function and improve patient outcomes. Through its dedicated research and development efforts, Otonomy aims to address the unmet medical needs of individuals suffering from various ear-related disorders. This commitment has positioned Otonomy as a leader in the field of otology.
Some significant milestones achieved by Otonomy Inc include the FDA approval of their product Otiprio, a treatment for pediatric patients with middle ear effusion, the successful completion of Phase 3 clinical trials for their product OTIVIDEX, a potential treatment for Meniere's disease, and the initiation of Phase 1/2 clinical trials for their product OTO-313, targeting tinnitus. Otonomy Inc has also entered into strategic partnerships and collaborations with companies like AGTC and CFFT to further advance their pipeline and enhance their expertise in gene therapy and cystic fibrosis. These accomplishments demonstrate Otonomy Inc's commitment to developing innovative solutions for hearing and balance disorders.
Otonomy Inc is primarily present in the United States.
Otonomy Inc represents a strong corporate philosophy centered around advancing hearing healthcare. They are committed to improving the lives of patients with ear and hearing disorders by developing innovative treatments. Otonomy Inc values patient-centricity, scientific excellence, and collaboration with healthcare professionals. They strive to deliver safe and effective therapies for various ear conditions, such as Meniere's disease and pediatric ear infections. With their dedication to research and development, Otonomy Inc aims to address unmet medical needs and enhance the quality of life for individuals suffering from ear-related ailments.
7 analysts currently rate the Otonomy stock: 6 recommend buying, 1 holding and 0 selling.
The Otonomy share (OTIC) is listed on 5 stock exchanges, including: NASDAQ (OTIC), SIX (Zürich) (7OT.SW), Frankfurt (7OT.F), München (7OT.MU), Düsseldorf (7OT.DU).
Otonomy Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of ear diseases. The company was founded in 2008 and is headquartered in San Diego, California. The company is divided into two business segments: Ear and Neurology. In the Ear segment, the company focuses on developing innovative products for the treatment of ear diseases such as hearing loss, tinnitus, and ear infections. In the Neurology segment, the company is dedicated to treating central nervous system disorders such as multiple sclerosis and migraine. One of Otonomy Inc's main products is OTIPRIO, an antibiotic for the treatment of acute middle ear infection in children. It is injected directly into the affected ear and reduces the need for systemic antibiotic therapy. OTIPRIO is the first and only product approved by the FDA for treating ear infections in a doctor's office. Another important product of Otonomy Inc is OTIVIDEX, a medication for treating patients with Meniere's disease, an inner ear disorder that causes dizziness, hearing loss, and ringing in the ears. OTIVIDEX has been studied in a clinical trial and has shown significant benefits compared to placebo. The company also has other products in development, including OTO-313, a medication for treating tinnitus, and OTO-413, a medication for treating hearing loss. Both products are in clinical trials. Otonomy Inc has a strong pipeline of products in development and is continuously working to expand its product range. This strategy is aimed at ensuring the long-term growth of the company and expanding treatment options for patients with ear and neurological diseases. The company's financing is primarily through the sale of stocks and investments from venture capital funds. The company went public in 2014. Overall, Otonomy Inc's business model is focused on developing and successfully commercializing innovative products for the treatment of ear and neurological diseases. The company relies on a strong pipeline of products in development to ensure long-term growth.
The revenue cannot currently be calculated for Otonomy.
The profit cannot currently be calculated for Otonomy.
The P/E ratio cannot be calculated for Otonomy at the moment.
The P/S cannot be calculated for Otonomy currently.
The Eulerpool Quality Score for Otonomy is 2/10.
The ISIN of Otonomy is US68906L1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Otonomy is A119VZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Otonomy is OTIC. The ticker symbol is used to trade Otonomy shares on the stock exchange.
Otonomy stock
Otonomy Peer Group
Otonomy Ticker
Otonomy FIGI
All fundamentals and in-depth analysis of Otonomy
Our stock analysis for Otonomy stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Otonomy. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.